Order online now!

www.rockland.com
tech@rockland.com
+1 484.791.3823

Datasheet for 200-103-240-0100

Fibrinogen Antibody Peroxidase Conjugated

Overview

Description:	Anti-FIBRINOGEN (Human Plasma) (GOAT) Antibody Peroxidase Conjugated - 200-103-240-0100
Item No.:	200-103-240-0100
Size:	100 µg
Applications:	Dot Blot, ELISA, IHC, WB
Reactivity:	Human
Host Species:	Goat

Product Details

Background:	Peroxidase Conjugated Anti-FIBRINOGEN Antibody is specific of fibrinogen protein. Fibrinogen is a soluble plasma glycoprotein synthesized by the liver that is converted by thrombin into fibrin during blood coagulation. Fibrin specifically binds the activated coagulation factors factor Xa and thrombin and entraps them in the network of fibers, thus functioning as a temporary inhibitor of these enzymes, which stay active and can be released during fibrinolysis. Recent research has shown that fibrin plays a key role in the inflammatory response and development of rheumatoid arthritis. Anti-FIBRINOGEN Antibody is suitable for immunology and cardiovascular research.
Synonyms:	goat anti-Fibrinogen Antibody HRP Conjugation, Peroxidase Conjugated goat anti-Fibrinogen Antibody, FGA antibody, FGA protein antibody, FGB antibody, FGG antibody, Fib2 antibody, Fibrinogen A alpha polypeptide antibody, Fibrinogen A alpha polypeptide chain antibody, Fibrinogen alpha chain antibody
Host Species:	Goat
Conjugate:	Peroxidase (HRP)
Clonality:	Polyclonal
Format:	IgG

Target Details

Gene Name:	FGA
Reactivity:	Human

Immunogen Type:	Native Protein
Immunogen:	Fibrinogen [Human Plasma]
Purity/Specificity:	Anti-FIBRINOGEN Antibody (Peroxidase Conjugated) is an IgG fraction antibody purified from monospecific antiserum by a multi-step process which includes delipidation, salt fractionation and ion exchange chromatography followed by extensive dialysis against the buffer stated above. Assay by immunoelectrophoresis resulted in a single precipitin arc against anti-Peroxidase, anti-Goat Serum as well as purified and partially purified Fibrinogen [Human Plasma]. Cross reactivity against Fibrinogen from other sources is unknown.
Relevant Links:	• NCBI - NP_000499.1 • UniProtKB - P02671 • GeneID - 2243

Application Details

Tested Applications:	Dot Blot, ELISA, IHC, WB
Application Note:	Anti-FIBRINOGEN Antibody (peroxidase conjugated) antibody has been tested by ELISA, dot blot, western blot, and immunohistochemistry. Concentrations should be optimized by researcher.
Assay Dilutions:	All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.
ELISA:	1:10,000 - 1:40,000
IHC:	1:250 - 1:1,000
WB:	1:1,000 - 1:5,000

Formulation

Physical State:	Lyophilized
Concentration:	1.0 mg/mL by UV absorbance at 280 nm
Buffer:	0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
Preservative:	0.01% (w/v) Gentamicin Sulfate. Do NOT add Sodium Azide!
Stabilizer:	10 mg/mL Bovine Serum Albumin (BSA) - Immunoglobulin and Protease free
Reconstitution Volume:	100 µL
Reconstitution Buffer:	Restore with deionized water (or equivalent)

Shipping & Handling

Shipping Condition:	Ambient
Storage Condition:	Store vial at 4° C prior to restoration. For extended storage aliquot contents and freeze at -20° C or below. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.
Expiration:	Expiration date is one (1) year from date of receipt.

Images



Fibrinogen quantification. Human fibrinogen (hFg) was incubated, overnight at 4 °C, on Thermoplastic polyurethane (TPU) Film, Brush, and Bar Coater. The adherent protein on TPU was detected through an anti-fibrinogen HRP-conjugated antibody (p/n 200-103-240) and quantified via ELISA assay. Data are represented as percentage of adherent hFg on TPU materials with respect to the TCP control (red line). Data are shown as the mean values of the replicates ($n = 3$) ± the standard deviation (SD), represented by the error bars. Statistically significant differences of samples vs. TCP were reported: $p < 0.0001$ (****), $p < 0.01$ (**). One-way analysis of variance (ANOVA), followed by Bonferroni's test between samples (#), was performed: $p < 0.05$.
Fig 7. PMID: 38248691
200-103-240

ELISA
Fibrinogen quantification. Human fibrinogen (hFg) was incubated, overnight at 4 °C, on Thermoplastic polyurethane (TPU) Film, Brush, and Bar Coater. The adherent protein on TPU was detected through an anti-fibrinogen HRP-conjugated antibody (p/n 200-103-240) and quantified via ELISA assay. Data are represented as percentage of adherent hFg on TPU materials with respect to the TCP control (red line). Data are shown as the mean values of the replicates (n = 3) ± the standard deviation (SD), represented by the error bars. Statistically significant differences of samples vs. TCP were reported: p < 0.0001 (****), p < 0.01 (**). One-way analysis of variance (ANOVA), followed by Bonferroni's test between samples (#), was performed: p < 0.05.
Fig 7. PMID: 38248691



Immunohistochemistry
Immunohistochemistry of Goat Anti-Fibrinogen antibody. Tissue: human liver tissue. Fixation: formalin fixed paraffin embedded. Antigen retrieval: not required. Primary antibody: Fibrinogen antibody at 1:500 for 1 h at RT. Secondary antibody: Peroxidase goat secondary antibody at 1:10,000 for 45 min at RT. Localization: Fibrinogen is localized in plasma. Staining: Fibrinogen as precipitated red signal with hematoxylin purple nuclear counterstain.



Western Blot
Western Blot of Goat anti-Fibrinogen antibody. Lane 1: Fibrinogen under reducing conditions. Lane 2: none. Load: 1 µg per lane. Primary antibody: Fibrinogen antibody at 1:3000 for overnight at 4°C. Secondary antibody: Dylight 488 conjugated Donkey anti goat secondary antibody at 1:10,000 for 45 min at RT. Block: TBS/MB-070 1 hr RT.

References

- Banerjee B. et al. Inhibitory activities of monoclonal antibodies against Staphylococcus aureus clumping factor A. *mBio.* (2025)
- Willems RAL et al. Patients with cirrhosis have a disbalance between coagulation and fibrinolysis resulting in a prothrombotic phenotype. *J Thromb Haemost.* (2025)
- Williams RAL et al. Altered whole blood thrombin generation and hyperresponsive platelets in patients with pancreatic cancer. *J Thromb Haemost.* (2024)
- Restivo E et al. Surface Properties of a Biocompatible Thermoplastic Polyurethane and Its Anti-Adhesive Effect against E. coli and S. aureus. *J Funct Bio,ater.* (2024)
- Tang Z. et al. Sensitive immunoassays of nitrated fibrinogen in human biofluids. *Talanta.* (2010)

Disclaimer